

Public release date: 1-May-2010

Contact: Vanessa Pavinato
media@esmo.org
41-091-973-1907
International Association for the Study of Lung Cancer

2nd European Lung Cancer Conference press program

Geneva, Switzerland (Palexpo), April 28– May 1, 2010

R. Calderone, IT

Zoledronic acid may improve survival in lung cancer patients with bone metastases (embargo: 28 April, 17:00 CEST)

In a retrospective audit, researchers have shown that lung cancer patients who are treated with zoledronic acid lived longer than those who did not receive the drug.



S. Otsuka, CA

CXCR4: a new drug target in lung cancer (embargo: 29 April, 16:15 CEST)

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not.

E. Jantus, ES

Spanish gene expression data promises targeting of anti-angiogenesis treatment (embargo: 29 April, 16:30 CEST)

Analyzing the expression of particular genes in lung cancers could soon allow researchers to identify groups of patients who are likely to benefit most from treatment with angiogenesis-inhibitor drugs.

C. Siedschlag, NL

Finding cancer 'cold spots' can help minimize radiotherapy side-effects (embargo: 30 April, 14:15)

Fine-tuning radiotherapy to take into account which parts of a patient's tumor are growing fastest could improve control of cancer while subjecting patients to lower doses of radiation.

F. Mornex, FR

First trial of pemetrexed with radiation and chemotherapy in lung cancer exclusively shows promising results (embargo: 29 April, 15:15 CEST)

The first trial of an important new combination therapy of treatment with the chemotherapy drug pemetrexed concurrent with radiation in lung cancer has delivered promising results.

C. Le Pechoux, FR

Meta-analysis: radiotherapy variants improve survival in non-metastatic lung cancer (embargo: 30 April, 16:15 CEST)

A new meta-analysis shows that patients with both non-small-cell lung cancer and small-cell lung cancer benefit in terms of overall survival when treated with hyperfractionated or accelerated radiotherapy.

N. Peguret, CH

4D-software helps adjust for breathing when treating lung cancer with radiotherapy (embargo: 30 April, 16:30 CEST)

A new 4-dimensional software program promises to improve the treatment of lung cancer by allowing doctors to take the movement of breathing into account when administering radiotherapy.

C. Udrescu, FR

Tool allows precise targeting of radiotherapy for cancer radiation therapy (embargo: 30 April, 16:45 CEST)

A system that allows precise targeting of radiotherapy using real-time X-ray images has allowed French doctors to increase the dose of radiation they administered to lung and liver cancers while minimizing harm to nearby healthy tissue.

R. Pirker, AT

Making personalized lung cancer therapy a reality in Europe (embargo: 30 April, 17:45 CEST)

Personalized therapy, in which treatment is based on the characteristics of an individual patient's tumor promised to improve outcomes for patients, as well as being more cost-effective and less toxic than existing treatments.

D. Carbone, US

Blood test may identify lung cancer patients likely to respond to erlotinib (embargo: 30 April, 18:15 CEST)

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib.

C. Genebes, FR

Lung cancer risk particularly high for heart and liver transplant recipients (embargo: 1 May, 8:00 CEST)

Heart and liver transplant recipients are at particularly high risk of developing lung cancer after receiving the donated organ.

The full conference program is available at <http://www.esmo.org/events/lung-2010-iaslc/program.html>

Appointments for media representatives

- **Round-table: The future of lung cancer research and treatment: where are we going? An insight from the ESMO and IASLC leading experts in lung cancer**

Wednesday, 28 April, 12:30-13:30 Room G

Paul Bunn, USA: IASLC Executive Director
Rolf Stahel, CH: ESMO Educational Committee Chair
Françoise Mornex, FR: 2nd ELCC Scientific Co-Chair
Rafael Rosell, ES: 2nd ELCC Scientific Co-Chair

Please find a list of toll-free telephone numbers for remote connection at the end of this document and online (www.esmo.org/newsroom)

- **Educational seminar for members of the media: Understanding personalized lung cancer therapy: How the anatomical extent of disease and staging, histology and molecular testing contribute to the equation**

Thursday, 29 April, 13:00-14:00 Room L

Moderators:

Dr. Peter Goldstraw, UK; Dr. Rafael Rosell, Spain

Experts and Topics:

Dr. Peter Goldstraw: Consultant Thoracic Surgeon, Royal Brompton Hospital;

Professor of Thoracic Surgery, Imperial College, London, UK; Past-Chair, IASLC Staging Project. He will give an overview of how lung cancer staging classification has changed, and clinical implications.

Dr. Paul Van Houtte: Head of the Department of Radiotherapy for the Institut Jules Bordet will discuss newer aspects of treatment planning to accurately target the anatomical extent of the disease.

Dr. Rolf Stahel: Senior Staff Physician at the Clinic and Policlinic of Oncology, University Hospital of Zürich and Titular Professor of Medicine at the University of Zürich, Switzerland, will explain the impact of histology on customizing systemic therapy of lung cancer

Dr. Fortunato Ciardiello: Associate Professor of Medical Oncology and head of the Laboratory of Experimental Molecular Therapeutics at the Cattedra di Oncologia Medica of the Seconda Università di Napoli, Naples, Italy; Chair of the ESMO Translational Research Working Group and member of the ESMO Educational Steering Committee. He will overview targeted therapy and perspectives of lung cancer molecular classification.

Please find a list of toll-free telephone numbers for remote connection at the end of this document and online (www.esmo.org/newsroom)

- **Press conference: Novel therapeutic approaches in lung cancer**
Friday, 30 April, 12:30-13:30 Room G

C. Genebes, J. Mazieres, FR: Screening for lung cancer in organ transplant recipients

C. Le Pecheux, FR: Hyperfractionated radiotherapy for patients with non-metastatic lung cancer: a meta-analysis helps resolve confusion

D. Carbone, US: Proteomic profiling for patients treated with erlotinib

Please find a list of toll-free telephone numbers for remote connection at the end of this document and online (www.esmo.org/newsroom)

Journalists will be able to attend the press conferences and the educational seminar both in person and remotely through toll-free dial-in.

Please contact the ELCC Press Office immediately at media@esmo.org to book a telephone hook-up, to schedule your remote interviews or register for the event

All sessions are open to journalists and registration is free to bona fide journalists on presentation of a valid press card and/or of a letter of assignment.

A media centre with computers, fax, printing, photocopying and free local and international telephone facilities and internet connections will be available to registered journalists.

###

For further information please contact:

Vanessa Pavinato
ELCC Press Office
Speakers/Press Center, Ground Floor, Geneva Palexpo
E-mail: media@esmo.org
Cell +41 (0)79 935 60 73
Office tel. +41 (0)22 761 24 01
Office fax +41 (0)22 761 24 02

Embargo Policy

All information presented at the 2nd European Lung Cancer Conference is embargoed until the time of the scientific presentation. Journalists are required to observe embargoes as indicated, thank you!
